Quanticel Pharmaceuticals and Celgene Corp. have entered into an exclusive, strategic collaboration to discover and develop first-in-class cancer drugs. Celgene will commit $45 million to Quanticel during the initial three-and-a-half-year alliance term, and has the option to extend the collaboration for additional funding. Celgene will also take an equity stake in Quanticel and will retain an exclusive option to acquire the company. Quanticel will use its platform to conduct single-cell genomic...